HHS Secretary Robert F. Kennedy Jr. Challenges FDA Peptide Restrictions as Former Officials Warn of Safety Risks

HHS Secretary Robert F. Kennedy Jr. may lift restrictions on 19 peptides. Former FDA officials warn the move mischaracterizes documented safety and efficacy risks.

By: AXL Media

Published: Apr 4, 2026, 6:12 AM EDT

Source: Information for this report was sourced from ProPublica

The Regulatory Dispute Over Compounding Pharmacy Ingredients

The burgeoning market for peptide therapies has become a primary battleground for the Department of Health and Human Services under the leadership of Robert F. Kennedy Jr. At the center of the conflict is a 2023 FDA decision that placed 19 peptides into "Category 2," a designation for substances deemed too risky for use by compounding pharmacies. Kennedy has publicly argued that the agency exceeded its legal authority by looking at the efficacy of these substances rather than strictly focusing on "safety signals." He contends that the lack of specific adverse event data makes the current restrictions invalid, positioning himself as an advocate for wider consumer access to these amino acid chains.

Former FDA Leadership Defends Scientific Oversight Protocols

In a direct rebuttal to the Secretary’s claims, former high-ranking FDA officials, including former acting commissioner Janet Woodcock, maintain that the agency followed established legal mandates. They argue that federal regulations require the FDA to assess both safety and effectiveness before a substance can be approved for the "bulks list" of compounding ingredients. Woodcock emphasized that bypassing these clinical requirements would represent a fundamental disruption of the "societal pact" established in 1962, which ensures that all drugs marketed in the United States are proven to work through rigorous study before reaching the public.

Documented Risks of Immune Responses and Manufacturing Impurities

The FDA’s original 2023 classification was informed by long-standing research indicating that synthetic injectable peptides carry significant risks of triggering unwanted immune responses. Because these drugs are modified to last longer in the body than naturally occurring peptides, the human immune system can recognize them as foreign invaders, leading to side effects ranging from localized rashes to life-threatening anaphylactic shock. Additionally, the manufacturing process for unapproved peptides often lacks the oversight necessary to prevent the introduction of heavy metals or bacterial contaminants, which pose a heightened risk when a substance is injected directly into the bloodstream.